ID

34328

Description

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4; ODM derived from: https://clinicaltrials.gov/show/NCT01057667

Lien

https://clinicaltrials.gov/show/NCT01057667

Mots-clés

  1. 16/01/2019 16/01/2019 -
  2. 14/04/2019 14/04/2019 -
  3. 15/04/2019 15/04/2019 -
Détendeur de droits

see on clinicaltrials.gov

Téléchargé le

16 janvier 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Hepatitis C, Chronic NCT01057667

Eligibility Hepatitis C, Chronic NCT01057667

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients, 18-70 years of age
Description

ID.1

Type de données

boolean

hepatitis c, genotype 1 or 4, of over 6 months duration
Description

ID.2

Type de données

boolean

treatment-naïve
Description

ID.3

Type de données

boolean

negative pregnancy test; female patients of childbearing age and male patients with female partners of childbearing age must use two forms of contraception during treatment and following the last dose of ribavirin in accordance with locally approved label for ribavirin
Description

ID.4

Type de données

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
pregnant or breast feeding females or male partners of pregnant females
Description

ID.5

Type de données

boolean

previous interferon or ribavirin based therapy or investigational anti-hcv agent
Description

ID.6

Type de données

boolean

systemic antiviral therapy with established or perceived activity against hcv </=3 months prior to first dose of study drug
Description

ID.7

Type de données

boolean

hepatitis a or b, or hiv infection
Description

ID.8

Type de données

boolean

history or evidence of medical condition associated with chronic liver disease other than hcv
Description

ID.9

Type de données

boolean

Similar models

Eligibility Hepatitis C, Chronic NCT01057667

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
adult patients, 18-70 years of age
boolean
ID.2
Item
hepatitis c, genotype 1 or 4, of over 6 months duration
boolean
ID.3
Item
treatment-naïve
boolean
ID.4
Item
negative pregnancy test; female patients of childbearing age and male patients with female partners of childbearing age must use two forms of contraception during treatment and following the last dose of ribavirin in accordance with locally approved label for ribavirin
boolean
Item Group
C0680251 (UMLS CUI)
ID.5
Item
pregnant or breast feeding females or male partners of pregnant females
boolean
ID.6
Item
previous interferon or ribavirin based therapy or investigational anti-hcv agent
boolean
ID.7
Item
systemic antiviral therapy with established or perceived activity against hcv </=3 months prior to first dose of study drug
boolean
ID.8
Item
hepatitis a or b, or hiv infection
boolean
ID.9
Item
history or evidence of medical condition associated with chronic liver disease other than hcv
boolean

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial